肺结核合并乙型肝炎病毒感染患者抗病毒与护肝治疗  

Antiviral and Liver Protection Treatment in Patients With Pulmonary Tuberculosis Complicated With Hepatitis B Virus Infection

作　　者：陆春雷[1] LU Chunlei(Department of Infectious Diseases,Affiliated Hospital of Youjiang Nationalities Medical College,Baise Guangxi 533000,China)

机构地区：[1]右江民族医学院附属医院感染性疾病科,广西百色533000

出　　处：《中国卫生标准管理》2020年第16期69-71,共3页China Health Standard Management

摘　　要：目的肺结核合并乙型肝炎病毒感染患者抗病毒与护肝治疗的疗效评价。方法随机抽样法选取2018年3月—2019年12月为研究时间区间,以此间在我院接受治疗的肺结核合并乙型肝炎病毒感染患者200例为研究对象。根据用药方式的不同将患者划分为对照组和研究组。其中采用抗结核、抗病毒实施治疗的患者归入对照组,采用甘草酸二铵联合抗结核、抗病毒治疗的患者归入研究组。以两组患者实施治疗后的肝脏损害情况、患者的HBe Ag转阴率和HBVDNA转阴率以及临床治疗效果为指标,对比分析两组患者的用药效果。结果两组患者的HBe Ag转阴率和HBV-DNA转阴率无明显差异(P>0.05);研究组患者治疗后的肝脏损害情况小于对照组;临床治疗有效率更高(P<0.05),治疗效果显著。结论对肺结核合并乙型肝炎病毒感染患者采用甘草酸二铵联合抗结核、抗病毒进行治疗,临床疗效显著,患者的肝脏损害情况得到了显著的好转,临床用药安全性更高,值得推广。Objective To evaluate the efficacy of antiviral and liver protection treatment in patients with pulmonary tuberculosis complicated with hepatitis B virus infection.Methods Random sampling method was selected from March 2018 to December 2019 as the study time interval.During this period,200 patients with pulmonary tuberculosis and hepatitis B virus infection treated in our hospital were selected as the research object.The patients were divided into a control group and a research group according to their different medication methods.Among them,patients treated with anti-tuberculosis and anti-virus were included in the control group,and patients with diammonium glycyrrhizinate combined with antituberculosis and anti-viral treatment were included in the research group.The liver damage situation,HBe Ag negative rate,HBV-DNA negative rate and clinical treatment effect of the two groups of patients were taken as the indicators,the drug effects of the two groups of patients were compared and analyzed.Results There was no significant difference in the HBe Ag negative rate and HBV-DNA negative rate between the two groups(P>0.05);the liver damage of the research group was less than that of the control group;the clinical treatment effective rate was higher,and the treatment effect was significant(P<0.05).Conclusion The treatment of patients with pulmonary tuberculosis and hepatitis B virus infection using diammonium glycyrrhizinate combined with anti-tuberculosis and anti-virus treatment has a significant clinical effect.The liver damage of the patients has been significantly improved,and the clinical drug safety is higher and it is worth promoting.

关 键 词：甘草酸二铵 抗病毒护肝治疗 肺结核 乙型肝炎病毒感染 肝脏损害情况 临床治疗效果 

分 类 号：R521[医药卫生—内科学]